In the PENELOPE-B trial, 1250 women with hormone receptor-positive, HER2-negative primary breast cancer without a pathological complete response after taxane-containing neoadjuvant chemotherapy, and at high risk of relapse, were randomized to receive 13 cycles of palbociclib 125 mg once daily or placebo. The gene discussed is NR4A1; the disease is breast carcinoma.